GlassScriptPhysician profile
Robert A Tufano
NPI 1851442966
$3,807.92
in general payments reported to CMS, 2019-2025
32 companies · $44.84 in 2025
The $44.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $1,036 · 2021: $873 · 2022: $639 · 2023: $116 · 2025: $44.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $160.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.54 | 2019-2023 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $598.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $350.10 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $320.08 | 2019-2023 | Seglentis, Livalo |
| Novo Nordisk INC | $220.36 | 2019-2022 | |
| Pfizer INC. | $217.68 | 2019-2023 | |
| Amarin Pharma, INC. | $183.96 | 2019-2021 | |
| Daiichi Sankyo INC. | $177.55 | 2020-2022 | |
| Allergan, INC. | $176.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.65 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.60 | 2019-2021 | |
| Neuronetics, INC. | $95.14 | 2022 | |
| Shire North American Group INC | $61.53 | 2019 | |
| Eisai INC. | $58.80 | 2020-2021 | |
| Lilly USA, LLC | $46.47 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $44.67 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $38.43 | 2022-2023 | Quviviq |
| Sanofi Pasteur INC. | $35.70 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $29.32 | 2019 | |
| Amgen INC. | $27.81 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $27.22 | 2022 | |
| Boston Scientific Corporation | $26.02 | 2021 | |
| Abbott Laboratories | $25.33 | 2022 | |
| Forte Bio-Pharma LLC | $24.98 | 2025 | Prolate, Nalocet, Tanlor |
| Redhill Biopharma INC. | $23.51 | 2021 | |
| Esperion Therapeutics, INC. | $22.45 | 2021 | |
| Renalytix Ai, INC. | $19.86 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Genentech USA, INC. | $17.32 | 2019 | |
| Smith+Nephew, INC. | $15.94 | 2019 | |
| Horizon Therapeutics Plc | $14.66 | 2022 | |
| Currax Pharmaceuticals LLC | $13.06 | 2019 | |
| Astellas Pharma US INC | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tufano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.